Nectar Lifesciences Limited

NSE NECLIFE.NS

Nectar Lifesciences Limited EBITDA Margin for the year ending March 31, 2024: 10.01%

Nectar Lifesciences Limited EBITDA Margin is 10.01% for the year ending March 31, 2024, a 182.78% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Nectar Lifesciences Limited EBITDA Margin for the year ending March 31, 2023 was 3.54%, a -62.74% change year over year.
Nectar Lifesciences Limited EBITDA Margin for the year ending March 31, 2022 was 9.50%, a 33.01% change year over year.
Nectar Lifesciences Limited EBITDA Margin for the year ending March 31, 2021 was 7.14%, a -23.20% change year over year.
Nectar Lifesciences Limited EBITDA Margin for the year ending March 31, 2020 was 9.30%, a -2.13% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: NECLIFE.NS

Nectar Lifesciences Limited

CEO	Mr. Amit Chadah
IPO Date	July 18, 2005
Location	India
Headquarters	SCO 38-39
Employees	1,686
Sector	Health Care
Industries Pharmaceuticals

Description

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

Key trends

Past 5 years